.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,367,657

« Back to Dashboard
Patent 8,367,657 protects BELVIQ XR and BELVIQ and is included in two NDAs.

This patent has forty-two patent family members in seventeen countries.

Summary for Patent: 8,367,657

Title:Processes for preparing 3-benzazepines
Abstract: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
Inventor(s): Wolgast; Beverly L. (San Diego, CA), Gilson, III; Charles A. (San Diego, CA), Aytes; Shelley (San Diego, CA), Estrada; Scott A. (La Jolla, CA), Sengupta; Dipanjan (San Diego, CA), Smith; Brian (San Diego, CA), Rey; Max (Wallisellen, CH), Weigl; Ulrich (Hilzingen, DE)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/560,953
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 122nd percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYes8,367,657► subscribeYY METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYes8,367,657► subscribeYY METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYes8,367,657► subscribeYY METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,367,657

PCT Information
PCT FiledJune 16, 2004PCT Application Number:PCT/US2004/019279
PCT Publication Date:March 03, 2005PCT Publication Number: WO2005/019179

Non-Orange Book Patents for Patent: 8,367,657

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,946,207Processes for preparing 3-benzazepines► subscribe
9,102,627Processes for preparing 3-benzazepines► subscribe
7,704,993Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,367,657

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2004253888► subscribe
Australia2004267016► subscribe
BrazilPI0411470► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc